Trerotola plans to retire effective upon the appointment of his successor by the board. As part of the company’s succession planning process, the board enlisted an executive search firm to identify the next Enovis CEO.
Upon the appointment of that CEO, to facilitate a smooth transition, Enovis and Trerotola plan to enter into a retirement and transition agreement. Trerotola agreed to continue to serve as an employee and exeuctive advisor for one year after the new CEO’s appointment.
“Working with the exceptionally talented team at Enovis has been a great honor,” said Trerotola. “I am deeply proud of all that we have accomplished over my tenure. Today, Enovis is a global company that is well positioned for continued growth thanks to our high-quality portfolio, focus on continuous improvement and exceptional team.
Trerotola said that, given the company’s “strong position,” he believes it’s the right time to transition to the next leader.
“The board is incredibly thankful for Matt’s years of stewardship at Enovis and Colfax,” said Sharon Wienbar, lead independent director. “Matt has been instrumental in driving Enovis’ transformation into a leading global MedTech innovator. Matt has played a pivotal role in shaping the company’s evolution, driving innovation and fostering a strong culture of excellence.
Enovis also releases fourth-quarter financial results
Enovis also today posted fourth-quarter results that came in ahead of the consensus forecast on Wall Street.
Shares of ENOV fell 1.6% to $41.44 apiece in early-morning trading today.
The Wilmington, Delaware-based company — one of the 10 largest orthopedic companies in the world — reported losses of $703.3 million. That equals $12.06 per share on sales of nearly $561 million for the three months ended Dec. 31, 2024.
Enovis recorded a massive bottom-line slide into the red despite a sales increase of 23.3%. The company noted that net losses from continuing operations included a non-cash goodwill impairment charge of $645 million related to a sustained decline in its stork price and market capitalization relative to the carrying value of its recon and P&R reporting units.
Adjusted to exclude one-time items, earnings per share came in at 98¢. That landed 6¢ ahead of expectations on Wall Street. Sales topped estimates by nearly 1%.
“Our performance in 2024 marks a transformational year for the Company as we executed our integration plans and solidified our ability to deliver sustainable high-single-digit organic growth and year-over-year margin expansion,” said Trerotola. “Our strong finish in 2024 has set a solid foundation for 2025 with key new product launches positioned to drive above market growth rates.”
Enovis expects adjusted EPS to range between $3.10 and $3.25 in 2025. It projects between $2.19 billion and $2.22 billion in sales.
